Orchestra BioMed enters $100M ATM sales agreement with TD Cowen, terminates Jefferies facility

Orchestra BioMed Holdings, Inc.

New sales agreement with TD Securities (USA) LLC for up to $100M of common stock in at-the-market offerings.
Prior $100M ATM agreement with Jefferies LLC terminated; $15.5M had been sold under it, $84.5M remained unused.
Termination intended to eliminate restrictions on Jefferies publishing research reports on the company.
Offering is under existing shelf registration statement (filed May 2024); no obligation to sell any shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.